Clinical experience with lisinopril in congestive heart failure. Focus on the older patient.
Lisinopril, a long acting, non-sulfhydryl-containing angiotensin-converting enzyme inhibitor, produces an increase in exercise capacity and an improvement in symptoms when administered in a dose of 5 to 20 mg/day to patients with congestive heart failure. There is an increase in left ventricular ejection fraction, and the effectiveness of the drug is not diminished by impairment of renal function (serum creatinine greater than 71.6 mg/dl). Lisinopril is just as effective in older (greater than 65 years of age) patients as in younger patients and is well tolerated among patients of all age groups.
Giles
T D
TD
Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
D000367:Age Factors; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004656:Enalapril / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D017706:Lisinopril
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D017706:Lisinopril